Literature DB >> 35449883

Machine learning techniques for arrhythmic risk stratification: a review of the literature.

Cheuk To Chung1, George Bazoukis2,3, Sharen Lee1, Ying Liu4, Tong Liu5, Konstantinos P Letsas6, Antonis A Armoundas7,8, Gary Tse1,4,5,9.   

Abstract

Ventricular arrhythmias (VAs) and sudden cardiac death (SCD) are significant adverse events that affect the morbidity and mortality of both the general population and patients with predisposing cardiovascular risk factors. Currently, conventional disease-specific scores are used for risk stratification purposes. However, these risk scores have several limitations, including variations among validation cohorts, the inclusion of a limited number of predictors while omitting important variables, as well as hidden relationships between predictors. Machine learning (ML) techniques are based on algorithms that describe intervariable relationships. Recent studies have implemented ML techniques to construct models for the prediction of fatal VAs. However, the application of ML study findings is limited by the absence of established frameworks for its implementation, in addition to clinicians' unfamiliarity with ML techniques. This review, therefore, aims to provide an accessible and easy-to-understand summary of the existing evidence about the use of ML techniques in the prediction of VAs. Our findings suggest that ML algorithms improve arrhythmic prediction performance in different clinical settings. However, it should be emphasized that prospective studies comparing ML algorithms to conventional risk models are needed while a regulatory framework is required prior to their implementation in clinical practice.

Entities:  

Keywords:  Artificial intelligence; Machine learning; Prediction models; Risk stratification; Ventricular arrhythmias; Ventricular fibrillation; Ventricular tachycardia

Year:  2022        PMID: 35449883      PMCID: PMC9020640          DOI: 10.1186/s42444-022-00062-2

Source DB:  PubMed          Journal:  Int J Arrhythmia        ISSN: 2466-0981


Introduction

Fatal ventricular arrhythmias (VAs) and sudden cardiac death (SCD) are some of the most important study outcomes in the field of cardiology. Current efforts have focused on the prediction of VAs in different diseases, including hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, heart failure (HF), congenital heart diseases, cardiac ion channelopathies, in addition to the risk of VAs among the general public [1-6]. Conventional risk scores are the most widely used tools for risk stratification purposes in clinical practice [7]. However, these risk scores have several limitations, including variations among validation cohorts, the inclusion of a limited number of predictors while omitting some variables that might be important. As a result, clinical scores that can accurately predict major outcomes and therefore can aid in personalized clinical management are needed. Machine learning (ML) can integrate and interpret data from different domains in settings where conventional statistical methods may not be able to perform [8]. Recently, the role of ML techniques has been studied in different aspects of medicine, including electronic health records, diagnosis, risk stratification, timely identification of abnormal heart rhythms in the intensive care unit [9, 10], on prognosis and guidance of personalized management [11, 12]. However, application of ML study findings has been limited due to the lack of a regulatory framework for its implementation and the clinicians’ unfamiliarity in using as well as trusting ML techniques [13]. This review aims to present existing data regarding the role of ML techniques in the risk stratification of VAs in different clinical settings.

Machine learning algorithms

ML algorithms can aid the interpretation of complex data, stratification of patient diagnosis and delivery of personalized care and therefore are particularly useful in the management of cardiovascular diseases [8]. Random forest, convolutional neural network (CNN) and long short-term memory network (LTSM) models are three commonly used ML approaches in cardiovascular medicine.

Random forest model

One common model ensemble method is known as the random forest model. The underlying idea of random forest algorithms originates from the assumption that predictions derived from a large ensemble of models are more accurate and robust compared to using a single model. Within a random forest model, numerous decision trees form the basic building blocks by performing either classification or regression tasks. To classify the data, it is processed through a series of true or false questions, allowing information to be categorized into the purest possible subgroups. Each decision tree will then classify a new object based on specific attributes through voting, and the classification is based on the largest sum of votes. In the case of regression, the average outputs from different trees are calculated [14]. With this algorithm, large data sets with higher dimensionality can be processed. When a group of uncorrelated decision trees in collaboration can reduce the effect of individual variability and errors, thus outperforming constituent trees [14]. There are two main ML ensemble meta-algorithms to ensure the trees are uncorrelated: bagging and featuring randomness. The former method separates the data into small subsets via random sampling with replacement, improving the stability of ML; at the same time, the latter shuffles specific features of the data set, increasing the diversity in trees. Due to the simplicity of individual trees, this lowers the training time and can be applied to academia, e-commerce and banking sectors. An illustration of one decision tree in a random forest model used to predict atrial fibrillation can be shown in Fig. 1 [15]. The model was trained with a sample of 682,237 Chinese subjects. In each decision tree, there was a maximum depth of four nodes. Any greater than four nodes in each tree were found to cause overfitting.
Fig. 1

First decision tree of the random forest model predicting risk of atrial fibrillation [15]

Convolutional neural networks

Convolutional neural networks (CNNs) are used to detect patterns and to classify images with a high level of precision using filters. Different types of filters detect various forms of patterns depending on their level of sophistication. Pattern detection can range from simple geometric shapes to complex objects such as eyes and dogs. The main purpose of a CNN is to receive and transform an input through a convolutional operation. In a convolutional operation, the process requires an input image, feature detector and feature map [14]. A feature detector consists of a matrix. The matrix can contain any digits corresponding to a specific color or feature that is being measured. This detector is placed over the input image, and the number of cells that match between the feature detector and the image is counted pixel by pixel. Often, CNN analysis may break down an image into smaller parts for higher precision during matching. After a series of calculations, this generates a feature map that indicates where a specific feature occurs. This process of convolving and filtering an image to generate a stack of filtered images is known as a convolution layer [14]. Realistically, for CNN to generate practical data, this would require multiple feature detectors to develop multiple feature maps. Following on, the output is passed onto an adjoining layer. This process is repeated until it reaches the final layer known as a fully connected layer, where a list of featured values converts into a list of votes for a category. Through training, CNN can prioritize the detection of features in chronological order with higher accuracy. An example of an optimal architecture of a CNN model used to predict atrial fibrillation can be demonstrated in Fig. 2 [16]. A one-dimensional convolution was used in the convolution layer as electrocardiographic (ECG) signals are also a one-dimensional time series. Other functions including dropout, batch normalization and a rectified linear unit were also included to prevent divergence.
Fig. 2

Seven-layered optimal architecture of the CNN model predicting risk of atrial fibrillation [16]

Long short-term memory network

Long short-term memory network (LTSM) is a type of gated recurrent neural network that regulates the flow of information. Hence, this allows the algorithm to learn to differentiate between unnecessary and relevant information for making predictions. The process begins with transforming a sequence of words into machine-readable vectors. These vectors are processed by transferring the previous hidden state into the next cell, which includes learned information from the previous network. Within an LSTM unit cell, there are three gates: The input gate controls whether the memory cell is updated, the output gate controls the visibility of the current cell state, and the forget gate ensures the memory cell is reset to 0. The previous and current inputs are combined to form a vector, which then goes through Tanh activation. Through a series of complex calculations and processing, LSTM can learn long-term dependencies. An example of an LTSM recurrent network architecture with focal loss, used to detect arrhythmia, is shows in Fig. 3 [17]. The four-layered LTSM network was designed to decipher the timing features in complex ECG signals, which is coupled with the focal loss to fix category imbalance. Epochs were set to 350 to achieve stability in classification accuracy.
Fig. 3

LSTM recurrent network architecture detecting arrhythmia on imbalanced ECG datasets [17]

Specific patient populations

ML algorithms have been used for arrhythmic risk stratification purposes and can provide an incremental value for the risk stratification of cardiomyopathies (Table 1).
Table 1

Summary of the baseline characteristics and the outcomes reported in ML studies provide data for risk stratification purposes

First authorYear of publicationEnrollment periodNumber of patientsAge (years)Males (%)Type of clinical settingMachine learning techniquePerformanceType of predicted arrhythmiaFeatures used for the prediction model
Hypertrophic cardiomyopathy
Alis [24]20202014–20196448.13 ± 13.0665.6HCMSVM, naïve Bayes, RF, k-NNAccuracy SVM: 82.8% Naïve Bayes: 83.3% RF: 82.8% k-NN: 93.8%Ventricular tachyarrhythmiamean LGE%
Bhattacharya [19]2019Mean duration: 2.86 years711No VA: 54 ± 15 Yes VA: 49 ± 1661.0HCMensemble of logistic regression and native Bayes classifiersSens: 73%, spe: 76%, C-index = 0.83Sustained VT, VF22 features identified as predictive of VAr by the HCM-VAr-Risk Model
Lyon [25]2018N/A12347 ± 1566.0HCMDensity-based clustering algorithmN/AVAData from 12 lead ECG holter
Smole [20]2021N/A230246 ± 1962.9HCMRF, XGBoost, SVM, NNAccuracy RF: 72% SVM (linear): 69% Bosted trees: 75% NN: 74% F1 score RF: 0.68 SVM (linear): 0.63 Boosted trees: 0.72 NN: 0,68VTdemographic characteristics, genetic data, clinical investigations, medications and disease-related events
Ischemic heart disease—heart failure—cardiomyopathies
Kotu [27]2015N/A54N/AN/APost-myocardial infarction patientsK-NN, SVM, decision tree, RFSVM classifier provided average accuracy of 92.6% and AUC of 0.921VAQuantitative discriminative features extracted from LGE-CMR image
Rogers [29]2021N/A4264.7 ± 13.097.6Ischemic CMPSVM, CNNAccuracy of the SVM: 83.2% Accuracy of convolutional NN: 56.7%VT/VFVentricular monophasic action potentials
Okada [28]20212003–201512260 ± 1187.0Ischemic CMPSVMAccuracy: 81% Correct classification: 86% NPP: 91%VALGE-CMR data
Au-yeung [67]2018NA7886077.3HFRF, SVMBoth RF and SVM methods achieve a mean AUC of 0.81 for 5-min prediction and mean AUC of 0.87–0.88 for 10-second predictionVentricular tachyarrhythmiaVA onset prediction with heart rate variability data from ICD
Meng [32]20192017–2019Retrospective: 500 Prospective: 1000N/AN/AHFrEFInformation gain ranking, decision trees, logistic regression, SVM, RF, ANNNA (study protocol)VT/VFDemographic, clinical, biological, electrophysiological, social and psychological variables
Wu [33]20202003–201538257 ± 1372.0HFrEFRFAUC: 0.88VAclinical heart failure course, baseline CMR imaging metrics, levels of the interleukin-6
Rocon [37]20202011–201710838.3 ± 15.548.1Non-compaction CMPSVD impute, Parameter Selection Algorithm, sequential forward selection, distance-weighted k-NNAccuracy: 75.5% Sens: 77% Spe: 75%Major adverse cardiovascular eventsLVEF (by CMRI), RV end systolic volume (by CMRI), RV systolic dysfunction (by echo) and RV lower diameter (by CMRI)
Implantable devices
Marzec [68]2018Minimum one year of observation235N/AN/APatients with implantable electronic devicesNaïve, RF, decision tree analysis, k-NN, SVMAccuracy Naïve: 74.5% RF: 76.6% Decision tree: 70.2% K-NN: 72.3% SVM: 74.5% F1 score Naïve: NA RF: 0.27 Decision tree: 0.13 K-NN: 0.00 SVM: NAVTData about physical daily activities
Shakibfar [35]2019N/A19,935N/AN/AICD patientsRFAccuracy: 96% AUC: 0.80VA (Electrical Storm)ICD variables
Channelopathies
Lee [43]20211997–201751650 ± 1692.0Brugada syndromeNonnegative matrix factorisation, RFRandom survival forest Precision: 83.4% Recall: 85.3% F1 score: 84.3% Nonnegative matrix factorization Precision: 87.1% Recall: 88.8% F1 score: 87.9%VT/VF, Brugada syndromeClinical and electrocardiographic data
Congenital heart disease
Dilller [51]202010 year observation period37216.054.8Tetralogy of FallotDeep learning algorithmsN/AVA prognosis, cardiac death, cardiac arrestPrediction of adverse outcome using CMR data
Sun [52]20212009 – 2019269N/A35.7Following ASD closure in pediatric patientsRF, SVM, K-nearest neighbor, AdaBoost, decision treeAccuracy k-NN: 78.9% Decision tree: 82.6% AdaBoost: 84.95% SVM: 89.3% RF: 94.7% AUC k-NN: 0.82 Decision tree: 0.80 AdaBoost: 0.75 SVM: 0.87 RF: 0.90Postoperative arrhythmiasDemographic characteristics, cardiac imaging data and blood exams
Different clinical settings
Sessa [49]2020January 2015–December 201618,01874.839.9Geriatric patientsConditional inference treeNAVASpecific medications
Taye [58]2019N/AN/AN/AN/APublic databasesANN classifiersAccuracy: 98.6% Sens: 98.4% Spe: 99%Ventricular tachyarrhythmiaQRS complex shape
Okada [42]20192000–20177653 ± 1059.0Cardiac sarcoidosisSupervised RFCorrect classification: 87% C-statistic: 0.91VA, atrioventricular blockRegional scar burden
Taye [57]2020N/A7820.7–75.380.8Spontaneous ventricular tachyar- rhythmia databaseCNN, k-NN, ANN, SVMAccuracy CNN: 84.6% ANN: 73.5% SVM: 67.9% k-NN: 65.9% AUC CNN: 0.78 ANN: 0.65 SVM: 0.63 k-NN: 0.62Ventricular tachyarrhythmiaHeart rate variability signals
Wu [54]20202012–201650830.83 ± 6.1775.0Young hypertensive patientsRecursive feature elimination, extreme gradient boostingC statistic: 0.757Composite endpoint including sustained VT/VFDemographics, medical history, vital signs, echocardiography, polysomnography, blood exams
Bergau [47]2018N/AN/AN/AN/AN/ASVMSens: 85% Spe: 90%Torsades de pointesGene expression differences
Chen [56]2021N/A17N/AN/AN/ASVM, RF, XGboostRF model with an average precision of 99.99% and recall of 88.98%VAHeartbeat interval time series
Yap [48]2004N/AN/AN/AN/AN/ASVM, probabilistic NN, k-NN, decision treeAccuracy SVM: 97.4% Probabilistic NN: 71.8% k-NN: 89.7% Decision tree: 38.5%Torsade de pointesSet of agents
Lee [55]20162013–2015N/AN/AN/AN/AANNSens: 88.2% Spe: 82.4% PPV: 83.3% NPV: 87.5%VT one hour prior to its occurrenceHeart rate variability and respiratory rate variability

HCM, hypertrophic cardiomyopathy; CMR, cardiac magnetic resonance; LGE, late gadolinium enhancement; VT, ventricular tachycardia; VA, ventricular arrhythmias; VF, ventricular fibrillation; SVM, support vector machine; SCD, sudden cardiac death; ANN, artificial neural network; HFrEF, heart failure with reduced ejection fraction; CMP, cardiomyopathy; ICD, implantable cardioverter-defibrillator; ASD, atrial septal defect; Sens, sensitivity; Spe, specificity; RF, random forest; CNN, convolutional neural network

Hypertrophic cardiomyopathy

A simple clinical score is recommended according to the current guidelines for the VA risk stratification of patients with hypertrophic cardiomyopathy (HCM) [18]. However, the analysis and implementation of more variables for VA risk stratification purposes seem to improve the predictive accuracy in this population. Specifically, the application of ML methods to electronic health data has identified new predictors of VAs in this population, while the ML-derived model performed better compared to current prediction algorithms [19]. In another study, the ensemble of logistic regression and naïve Bayes classifiers was most effective in separating patients with and without Vas [19]. A recent study proposed a novel ML risk stratification tool for the prediction of five-year risk in HCM, which showed a better performance compared to conventional risk stratification tools regarding SCD, cardiac and all-cause mortality, while the best performance was achieved using boosted trees [20]; specifically, the authors used demographic characteristics, genetic data, clinical investigations, medications and disease-related events for risk stratification purposes. Cardiac magnetic resonance (CMR) has been found to provide important data for risk stratification purposes in HCM patients [21]. Of the studied CMR indices, late gadolinium enhancement (LGE) has a major role in the risk stratification of this population [22]. The extent of LGE has been found to outperform current guideline-recommended criteria in the identification of HCM patients at risk of Vas [23]. In this context, ML techniques can improve the accuracy in the identification of high-risk patients. Specifically, ML-based texture analysis of LGE-positive areas has been proposed as a promising tool for the classification of HCM patients with and without ventricular tachycardia (VT) [24]. In this study, of eight ML models investigated, k-nearest-neighbors with synthetic minority oversampling technique depicted the best diagnostic accuracy for the presence or absence of VT [24]. 12-lead Holter ECGs have also been analyzed using mathematical modeling and computational clustering to identify phenotypic subgroups of HCM patients [25]. Specifically, using these methods, it has been found that HCM can be classified into patients with T-wave inversion with and without secondary to QRS abnormalities. HCM patients with T-wave inversion not secondary to QRS abnormalities have been associated with an increased risk of SCD [25].

Other cardiomyopathies

The risk stratification of fatal arrhythmias is also significant in myocardial infarction patients. CMR has also been found to provide incremental data for risk stratification purposes in this population [26]. Quantitative discriminative features extracted from LGE in post-myocardial infarction patients have been studied for the discrimination of high- versus low-risk patients. In a study, the leave-one-out cross-validation scheme was implemented to classify high- and low-risk groups with a high classification accuracy for a feature combination that captures the size, location and heterogeneity of the scar [27]. Furthermore, nested cross-validation was performed with k-neural network, support vector machine, adjusting decision tree and random forest classifiers to differentiate high-risk and low-risk patients. In this context, the support vector machine classifier provided average accuracy of 92.6% and area under the receiver operating curve (AUC) of 0.921 for a feature combination capturing location and heterogeneity of the scar [27]. Recently, a novel ML approach was studied for quantifying the three-dimensional spatial complexity of grayscale patterns on LGE-CMR images to predict VAs in patients with ischemic cardiomyopathy [28]. Specifically, in this study, a substrate spatial complexity profile was created for each patient. The ML algorithm was classified with 81% overall accuracy, while the overall negative predictive value was estimated at 91% [28]. The clinical importance of these findings is mainly attributed to the high negative predictive value of the method that can identify ischemic cardiomyopathy patients who will not be benefited from an implantable cardioverter-defibrillator (ICD). Except for clinical and imaging variables, cellular electrophysiological characteristics have also been studied using ML algorithms to identify ischemic cardiomyopathy patients at risk of SCD [29]. ML of monophasic action potential recordings in ischemic cardiomyopathy patients revealed novel phenotypes for predicting sustained VT/fventricular fibrillation (VF) [29]. Another clinical entity that needs a better risk stratification tool is HF with reduced ejection fraction (HFrEF) due to non-ischemic dilated cardiomyopathy. While previous studies had proved the benefit of ICDs in the primary prevention of SCD in this setting [30], the Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH) trial showed that prophylactic ICD implantation in patients with symptomatic systolic HF that not caused by coronary artery disease was not associated with a significantly lower rate of all-cause mortality [31]. It is of great clinical importance to identify those patients with HFrEF due to non-ischemic etiology, who will benefit from an ICD. ML techniques can play a crucial role in better stratifying this group of patients [32]. In a recent study, ML techniques were used to identify cardiac imaging and time-varying risk predictors of appropriate ICD therapy in HFrEF patients [33]. It was found that baseline CMR imaging metrics (specifically, left ventricle heterogeneous gray and total scar, left ventricle and left atrial volumes, and left atrial total emptying fraction) and interleukin-6 levels were the strongest predictors of subsequent appropriate ICD therapies [33]. It is well known that ICD shocks have been associated with adverse events in patients with ICDs [34]. ML techniques and specifically random forest have been used for the prediction of short-term risk of electrical storm in patients with an ICD using daily summaries of ICD measurements [35]. The clinical importance of these methods can be mainly attributed to the preventive measures that can be adopted to avoid an imminent arrhythmic event. ML algorithms can further improve the existing risk stratification tools, and the ML-derived models can help clinicians to optimize the management of HFrEF patients. Non-compaction cardiomyopathy is another clinical setting that needs further research for better characterization and risk stratification. In a recent study, the presence of significant compacted myocardial thinning, an elevated B-type natriuretic peptide or increased left ventricular dimensions were significantly associated with adverse events in non-compaction cardiomyopathy patients [36]. ML techniques have been implemented for improving risk stratification in these patients. Specifically, echocardiographic and CMR data were analyzed using ML algorithms to identify predictors of adverse events in non-compaction cardiomyopathy patients [37]. The combination of CMR-derived left ventricular ejection fraction, CMR-derived right ventricular end systolic volume, echocardiogram-derived right ventricular systolic dysfunction and CMR-derived right ventricular lower diameter was found to achieve the better performance in predicting major adverse events in these patients [37].

Sarcoidosis

Cardiac sarcoidosis is another clinical condition that mandates a better arrhythmic risk stratification model given the increased risk of complete heart block, VA and SCD. Currently, an ICD should be considered in patients with atrioventricular block requiring pacemaker implantation independently of the left ventricular ejection fraction [38]. ML techniques have been used for diagnosing and optimizing the arrhythmic risk stratification of these patients. While the 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) plays a critical role in the diagnosis of cardiac sarcoidosis, there are significant interobserver differences that warrant more objective quantitative evaluation methods, which can be achieved by ML approaches [39]. It has been reported that deep CNN analysis can achieve superior diagnostic performance of sarcoidosis in comparison with the conventional quantitative analysis [40]. Moreover, it is known that myocardial scarring on CMR has a prognostic value in cardiac sarcoidosis patients [41]. A ML approach using regional CMR analysis predicted the combined endpoint of death, heart transplantation or arrhythmic events with reasonable accuracy in cardiac sarcoidosis patients [42].

Ion channelopathies

Specific clinical and electrocardiographic markers have been associated with VT/VF occurrence in patients with Brugada syndrome. ML techniques can further improve the risk stratification performance of existing prediction models. Specifically, the combination of nonnegative matrix factorization and random forest models showed the best predictive performance compared with the random forest model alone and Cox regression models in this clinical setting [43]. Similarly, the random forest can better predict the occurrence of VT/VF post-diagnosis in congenital long QT syndrome in comparison with the conventional multivariate Cox regression model [44]. Furthermore, ML approaches can be used to explore the associations between genetic mutations and the occurrences of VAs triggered by ion channelopathies. As mutations of the SCN5A gene are known to be associated with Brugada syndrome and long QT syndrome, a study has applied ML methods to a list of missense SCN5A mutations and found mutations causing changes to the sodium current increase the risk of Vas [45]. However, the location, rather than the physicochemical properties of the mutation, is predictive, which highlights that functional studies remain important in this area of research [45]. As with Brugada and long QT syndromes, random forest analysis has been applied to identify important factors of ventricular arrhythmogenesis in catecholaminergic polymorphic VT [46].

Drug-induced arrhythmias

Another interesting area pertinent to the implementation of ML techniques involves the prediction of drug-induced VAs. Specifically, using a support vector machine classifier, clustering by gene expression profile similarities showed that certain drugs prolong the QT interval in a limited number of patient groups [47]. As a result, ML methods may provide additional benefit in the current process of testing ion channel activities in the preclinical setting of cardiac safety assessment of drugs. Support vector machine has also been used for the prediction of Torsade des pointes of the different pharmacological agents [48]. It should be mentioned that ML methods have not only been implemented to identify a potential association between drugs and arrhythmic risk but also to identify moderators of the arrhythmic potential of specific medications [49]. Specifically, a study previously constructed a surrogate model for QT interval using multi-fidelity Gaussian regression and found that compounds blocking the rapid delayed rectifier potassium channels have the greatest QT-prolonging effect [50].

Congenital structural heart disease

An integrated approach should be implemented in patients with complex congenital structural heart disease for the early prediction of adverse outcomes. For example, patients with Tetralogy of Fallot require risk stratification for the early identification of high-risk patients who require advanced healthcare management. ML techniques and specifically deep learning imaging analysis have been proposed to improve the risk stratification of Tetralogy of Fallot patients [51]. Using CMR data, a composite score of the enlarged right atrial area and depressed right ventricular longitudinal function identified a tetralogy of Fallot subgroup at increased risk of adverse outcome [51]. Furthermore, ML techniques have also studied in the prediction of postoperative arrhythmias following atrial septal defect closure. In this setting, a prediction model based on synthetic minority oversampling technique algorithm and the random forest was found to predict arrhythmias with excellent accuracy in a pediatric population [52]. This is further supported by Guo et al., which used a combination of ML techniques including support vector machine (SVM), random forest, naïve Bayes and adaptive boost to predict postoperative blood coagulation function for children with congenital heart disease [53]. The results offer promising evidence that ML models are more robust and accurate relative to traditional statistical methods.

Arterial hypertension

Hypertension is a common condition that has been associated with adverse outcomes in the long-term setting. However, a prediction model is difficult to be constructed in young hypertensive patients mainly due to the lack of sufficient data in this population. Wu et al. used two ML methods, recursive feature elimination and extreme gradient boosting, to predict outcomes in young patients with hypertension [54]. The outcome was the composite of all-cause mortality, acute myocardial infarction, coronary artery revascularization, new-onset HF, new-onset atrial fibrillation/atrial flutter, sustained VT/VF, peripheral artery revascularization, new-onset stroke and end-stage renal disease [54]. While the proposed ML model was comparable with Cox regression for the measured outcome in the young patients with hypertension, it performed better than that of the recalibrated Framingham Risk Score model [54].

Discussion

The role of ML algorithms for the risk stratification of VAs has been studied in different clinical settings. ML algorithms can provide an incremental value for the risk stratification of cardiomyopathies (HCM, ischemic and non-ischemic cardiomyopathy), cardiac sarcoidosis, channelopathies, congenital heart disease, arterial hypertension, as well as in predicting pharmacologically induced life-threatening arrhythmias. The management and especially the prediction of life-threatening arrhythmias are paramount in clinical cardiology. A prediction model for VT one hour before its occurrence, using an artificial neural network, has been generated using 14 parameters obtained from heart rate variability and respiratory rate variability analysis [55]. ML techniques have been used to predict the occurrence of VAs using heartbeat interval time series. In this setting, the random forest model showed better performance using a length of heartbeat interval time series of 800 heartbeats, 108 s before the occurrence of arrhythmias [56]. These results can be implemented mainly in the prevention of cardiac arrest identifying high-risk patients prior to the occurrence of life-threatening VAs. Another study proposed a CNN algorithm to predict the onset of a VT using heart rate variability data [57]. The authors found that compared to other ML algorithms, the proposed one showed the highest prediction accuracy. Furthermore, ML algorithms have also been used for the prediction of VF. In this setting, QRS complex shape features were analyzed using artificial neural network classifiers [58]. This proposed model was found to achieve a better performance compared to the prediction accuracy using heart rate variability features [58]. Another area of ML implementation is in in-hospital monitoring. Timely and accurate discrimination of shockable versus non-shockable rhythms from external detectors and ICDs is of great clinical importance. Recently, the fixed frequency range empirical wavelet transform filter bank and deep CNN were used to analyze electrocardiographic signals [59]. The results showed excellent accuracy rates in classifying shockable versus non-shockable rhythms, VF versus non-VF and VT versus VF [59]. A deep learning architecture based on one-dimensional CNN layers and an LSTM network was found to be timely and accurate for the detection of VF in automated external defibrillators [60]. Furthermore, ML-based intensive care unit alarm systems have been found to achieve higher positive predictive values for the identification of asystole, extreme bradycardia, VT and VF compared to the bedside monitors used in the PhysioNet 2015 competition [9, 10, 61]. Except for life-threatening arrhythmias, ML algorithms have been used for the management of atrial fibrillation. Artificial intelligence-enabled electrocardiography was used to predict the incident atrial fibrillation [62]. In the same setting, ML algorithms have been implemented and outperformed conventional tools for the prediction of atrial fibrillation in critically ill patients who were hospitalized with sepsis [63]. In the field of invasive management of atrial fibrillation, ML-based classification of 12-lead ECG has been proposed as a useful tool for guiding atrial fibrillation ablation procedures and specifically in identifying patients suitable for pulmonary vein isolation alone vs. those needing additional ablation to pulmonary vein isolation [64]. Moreover, an ensemble classifier that used clinical and heart rate variability features were found to predict atrial fibrillation catheter ablation outcomes [65]. As a result, ML algorithms can have a role in the prevention and management of patients at risk or with documented atrial fibrillation, respectively. However, ML algorithms present a series of limitations. Not only does ML require large sets of data during training, a considerable amount of time and resources is also necessary. Moreover, ML algorithms are susceptible to errors, such as mislabeled data, overfitting information and unavoidable bias [66]. Furthermore, ML techniques can only be trained to analyze a specific type of data; for example, although the random forest is highly effective in performing classification tasks, it is less effective when performing regression tasks as the algorithm cannot demonstrate precise, continuous nature predictions. Similarly, CNN is only effective in analyzing spatial patterns in images. Resultantly, different ML algorithms should be used for different purposes. Finally, ML algorithms shine a light on the debate regarding transparency, authority and other ethical ramifications. Therefore, an established framework that regulated the implementation of ML in clinical practice needs to be implemented [13].

Conclusions

ML algorithms have been shown to ameliorate arrhythmic prediction performance in different clinical settings. However, it should be emphasized that prospective studies comparing ML algorithms to conventional risk models are needed while a framework is required prior to their implementation in clinical practice.
  65 in total

1.  The feasibility of predicting impending malignant ventricular arrhythmias by using nonlinear features of short heartbeat intervals.

Authors:  Zheng Chen; Naoaki Ono; Wei Chen; Toshiyo Tamura; M D Altaf-Ul-Amin; Shigehiko Kanaya; Ming Huang
Journal:  Comput Methods Programs Biomed       Date:  2021-04-15       Impact factor: 5.428

2.  Detection of shockable ventricular cardiac arrhythmias from ECG signals using FFREWT filter-bank and deep convolutional neural network.

Authors:  Rohan Panda; Sahil Jain; R K Tripathy; U Rajendra Acharya
Journal:  Comput Biol Med       Date:  2020-07-29       Impact factor: 4.589

3.  Cardiac magnetic resonance image-based classification of the risk of arrhythmias in post-myocardial infarction patients.

Authors:  Lasya Priya Kotu; Kjersti Engan; Reza Borhani; Aggelos K Katsaggelos; Stein Ørn; Leik Woie; Trygve Eftestøl
Journal:  Artif Intell Med       Date:  2015-07-04       Impact factor: 5.326

4.  A review of risk prediction models in cardiovascular disease: conventional approach vs. artificial intelligent approach.

Authors:  Aizatul Shafiqah Mohd Faizal; T Malathi Thevarajah; Sook Mei Khor; Siow-Wee Chang
Journal:  Comput Methods Programs Biomed       Date:  2021-05-21       Impact factor: 5.428

5.  A novel risk model for predicting potentially life-threatening arrhythmias in non-ischemic dilated cardiomyopathy (DCM-SVA risk).

Authors:  Elham Kayvanpour; Arjan Sammani; Farbod Sedaghat-Hamedani; David H Lehmann; Alicia Broezel; Jan Koelemenoglu; Przemysław Chmielewski; Angelique Curjol; Pierre Socie; Tobias Miersch; Jan Haas; Weng-Tein Gi; Pascale Richard; Rafał Płoski; Grażyna Truszkowska; Annette F Baas; Bogna Foss-Nieradko; Ewa Michalak; Małgorzata Stępień-Wojno; Joanna Zakrzewska-Koperska; Mateusz Śpiewak; Tomasz Zieliński; Eric Villard; Anneline S J M Te Riele; Hugo A Katus; Norbert Frey; Zofia T Bilińska; Philippe Charron; Folkert W Asselbergs; Benjamin Meder
Journal:  Int J Cardiol       Date:  2021-07-07       Impact factor: 4.164

6.  Novel Approach to Risk Stratification in Left Ventricular Non-Compaction Using A Combined Cardiac Imaging and Plasma Biomarker Approach.

Authors:  Jay Ramchand; Pooja Podugu; Nancy Obuchowski; Serge C Harb; Michael Chetrit; Alex Milinovich; Brian Griffin; Louise M Burrell; W H Wilson Tang; Deborah H Kwon; Scott D Flamm
Journal:  J Am Heart Assoc       Date:  2021-04-09       Impact factor: 5.501

7.  Territory-wide cohort study of Brugada syndrome in Hong Kong: predictors of long-term outcomes using random survival forests and non-negative matrix factorisation.

Authors:  Sharen Lee; Jiandong Zhou; Ka Hou Christien Li; Keith Sai Kit Leung; Ishan Lakhani; Tong Liu; Ian Chi Kei Wong; Ngai Shing Mok; Chloe Mak; Kamalan Jeevaratnam; Qingpeng Zhang; Gary Tse
Journal:  Open Heart       Date:  2021-02

8.  Prediction of arrhythmia after intervention in children with atrial septal defect based on random forest.

Authors:  Hongxiao Sun; Yuhai Liu; Bo Song; Xiaowen Cui; Gang Luo; Silin Pan
Journal:  BMC Pediatr       Date:  2021-06-16       Impact factor: 2.125

9.  Prediction of Ventricular Tachycardia One Hour before Occurrence Using Artificial Neural Networks.

Authors:  Hyojeong Lee; Soo-Yong Shin; Myeongsook Seo; Gi-Byoung Nam; Segyeong Joo
Journal:  Sci Rep       Date:  2016-08-26       Impact factor: 4.379

10.  Predicting changes to INa from missense mutations in human SCN5A.

Authors:  Michael Clerx; Jordi Heijman; Pieter Collins; Paul G A Volders
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

View more
  1 in total

Review 1.  Clinical significance, challenges and limitations in using artificial intelligence for electrocardiography-based diagnosis.

Authors:  Cheuk To Chung; Sharen Lee; Emma King; Tong Liu; Antonis A Armoundas; George Bazoukis; Gary Tse
Journal:  Int J Arrhythmia       Date:  2022-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.